E

Exact Sciences Corp
D

EXAS

53.530
USD
-0.46
(-0.85%)
مغلق
حجم التداول
46,505
الربح لكل سهم
-0
العائد الربحي
-
P/E
-10
حجم السوق
10,097,774,636
أصول ذات صلة
ABBV
ABBV
-1.290
(-0.67%)
191.070 USD
BAX
BAX
-0.760
(-2.42%)
30.610 USD
BDX
BDX
-2.215
(-1.27%)
172.245 USD
BSX
BSX
1.190
(1.21%)
99.750 USD
GILD
GILD
-2.080
(-1.86%)
110.010 USD
ILMN
ILMN
-1.120
(-1.27%)
87.000 USD
MDT
MDT
-1.240
(-1.40%)
87.270 USD
M
MYGN
-0.16000
(-3.08%)
5.04000 USD
SYK
SYK
-3.14
(-0.83%)
377.30 USD
T
TNDM
-0.165
(-0.79%)
20.760 USD
VRTX
VRTX
-4.36
(-0.95%)
455.70 USD
المزيد
الأخبار المقالات

العنوان: Exact Sciences Corp

القطاع: Healthcare
الصناعة: Diagnostics & Research
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, aliquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.